Stocksigma LogoStocksigma Logo

Anthem Biosciences Reports Strong Q2FY27 Results with PAT Up 21.9% YoY

Anthem Biosciences reported a 7.9% YoY increase in Q2FY27 consolidated revenue from operations to ₹5,940 Mn (up 42.0% QoQ), led by CRDMO revenue of ₹5,093

Anthem Biosciences Reports Strong Q2FY27 Results with PAT Up 21.9% YoY

Anthem Biosciences Ltd · Press Release · 03 Nov 2026, 11:37 pm

Anthem Biosciences Reports Strong Q2FY27 Results with PAT Up 21.9% YoY Anthem Biosciences reported a 7.9% YoY increase in Q2FY27 consolidated revenue from operations to ₹5,940 Mn (up 42.0% QoQ), led by CRDMO revenue of ₹5,093 Mn (up 9.2% YoY). EBITDA grew 24.1% YoY to ₹3,304 Mn with EBITDA margins reaching 50.6%, while PAT rose 21.9% YoY to ₹2,115 Mn with a 32.4% margin. For H1 FY27, revenue stood at ₹10,123 Mn, EBITDA at ₹5,059 Mn (46.2% margin), and PAT at ₹3,314 Mn. As of 30th Sep'26, the company held a net cash position of ₹15,380 Mn.

Original exchange filing (PDF)

More announcements from Anthem Biosciences Ltd

All Anthem Biosciences Ltd announcements